New Delhi: India’s first indigenously developed covid-19 vaccine ‘COVAXIN’ will be available for the children by September, Says Delhi AIIMS chief Dr. Randeep Guleria.
Guleria in a special interview with media said “Covaxin’s data for children after completion of the Phase 2/3 trials will be available by September and the approval is expected the same month.”
According to Guleria, Pfizer-BioNTech’s vaccine receives approval in India then that can also be one of the options for children. On June 7, Delhi AIIMS started vaccine clinical trials on kids between the age of 2 to 17.
AIIMS Chief already warned for the third wave in the nation and in his statement, he said that that third wave of COVID-19 can strike India in the next six to eight weeks if crowds are not prevented and if rules are broken.
According to a media report – On June 22, the Subject Expert Committee (SEC) accepted and approved the phase 3 trial data of Covaxin which showed 77.8 percent efficacy. This data will now be sent to the DCGI for review.
The government of India and the state government are trying to vaccinate maximum people in a very short time.